# Vivos Therapeutics, Inc. (VVOS) — management_change/cfo [completed]
Source: SEC API (secapi.ai) · situation sit_8a4f687d51ef0cc44d56 · retrieved 2026-08-12T21:26:02.812Z

## Overview
Vivos Therapeutics, Inc. is a surgical and medical instruments company listed on Nasdaq under ticker VVOS.

Bradford Amman resigned as Chief Financial Officer and Secretary of Vivos Therapeutics, Inc. effective July 31, 2026, on a voluntary and mutually agreed basis. Amman will remain as a non-executive transition employee for 90 days serving as Principal Accounting Officer, then transition to a 180-day advisory period as an independent contractor at $13,333 monthly. Effective July 31, 2026, Roman Franklin was appointed Chief Financial Officer and Principal Financial Officer. Pursuant to a Master Services Agreement with The CFO Portal, LLC (of which Franklin is CEO), Franklin will receive a fixed monthly retainer of $27,000 and a non-qualified stock option to purchase 552,000 shares of common stock vesting in twelve equal monthly tranches, with an exercise price equal to the Nasdaq closing price on the grant date. The option vests in full upon termination without cause, resignation for good reason, or a change in control. Amman will receive a fully vested award of 250,000 shares and a stock option to purchase 150,000 shares (vesting monthly during the Advisory Period at $0.40 or higher), subject to Board approval and effectiveness of a release of claims.

## Terms
- Counterparty: The CFO Portal, LLC; Roman Franklin · Consideration: mixed · Price/share: $0.4

## Key dates
- Completed 2026-07-31

## Timeline
- 2026-08-03 · 8-K (0001493152-26-035867): 8-K - Vivos Therapeutics, Inc. — *Vivos Therapeutics, Inc. is a surgical and medical instruments company listed on Nasdaq under ticker VVOS.* Bradford Amman resigned as Chief Financial Officer and Secretary of Vivos Therapeutics, Inc. effective July 31, 2026, on a voluntary and mutually agreed basis. Amman will remain as a non-executive transition employee for 90 days serving as Principal Accounting Officer, then transition to a 180-day advisory period as an independent contractor at $13,333 monthly. Effective July 31, 2026, Roman Franklin was appointed Chief Financial Officer and Principal Financial Officer. Pursuant to a Master Services Agreement with The CFO Portal, LLC (of which Franklin is CEO), Franklin will receive a fixed monthly retainer of $27,000 and a non-qualified stock option to purchase 552,000 shares of common stock vesting in twelve equal monthly tranches, with an exercise price equal to the Nasdaq closing price on the grant date. The option vests in full upon termination without cause, resignation for good reason, or a change in control. Amman will receive a fully vested award of 250,000 shares and a stock option to purchase 150,000 shares (vesting monthly during the Advisory Period at $0.40 or higher), subject to Board approval and effectiveness of a release of claims.
  https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-035867.txt

## Citations
- 0001493152-26-035867 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226035867